Abstract Unique biological properties of stem cells make them a precious source of cell material for treatment of a number of pathological conditions. Among issues inhibiting transition of stem cell technologies to the clinics, the risk of oncological complications of stem cell-based therapies is the most critical. A massive amount of clinical and experimental data demonstrates that both hematological (including acute and chronic myeloid leukemia) and nonhematological (including teratoma and non-teratoma tumors) malignancies could arise from donor stem cells of different types. A wide spectrum of mechanisms could underlie the development of oncological disease in recipients, including: i) blast transformation of proliferating donor stem cells under persistent action of certain factors in the recipient, thus causing de novo malignancies; ii) contamination of donor cell material with malignant cells; iii) transmission of particular viral subtypes with donor stem cells, combined with immunosuppression therapy effects; iv) uncontrollable proliferation of residual undifferentiated stem cells of various plasticity; and v) karyotypic instability in stem cells following prolonged culturing/ expansion in vitro. Potential preventive strategies are diverse and include i) high-throughput cell sorting-based strategies; ii) introduction of suicide genes into the donor stem cell genome; iii) application of apoptosis-inducing epigenetic factors; and some other options.
Introduction
Stem cells play a key role in tissue and organism growth, maturation and regeneration. Some stem cell types (primarily, bone marrow, umbilical cord and peripheral blood stem cells) have been used in clinics for decades (bone marrow stem cells-since 1968) for an expanding number of clinical indications. In clinical hematology, autologous and/or allogenic hematopoietic stem cell transplantation is indicated in specific clinical cases of leukemia, lymphoma and plasma cell disorders, providing a life-saving treatment for many thousands of adult and juvenile patients. Moreover, unique biological properties of stem cells (and not bone marrow stem cells alone) make these cell types a promising resource for cell replacement or regenerative therapeutic approaches already applied, or currently being developed for non-hematological disorders, including severe trauma and burns, solid tumors, autoimmune disorders, Parkinson's disease, diabetes mellitus, etc. Many stem cell types, including mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs), have been extensively evaluated for their ability to serve as substrates for cell replacement or regenerative therapies. We are currently seeing a transition of stem cell technologies to the clinics in a number of new fields, introducing novel, highly effective treatments. However, over the decades of stem cell transplantation, it has become evident that donor stem cells could cause malignancies in recipients. Thought to be rare in clinical practice or so far only detected in the laboratory, risks associated with development of stem cell transplantationrelated malignancies constitute a serious potential threat to patient health. A massive amount of clinical and experimental data accumulated to date demonstrates that both hematological (donor cell leukemia (DCL)) and non-hematological (including teratoma and non-teratoma tumors) malignancies could arise from donor stem cells of different types. A wide spectrum of mechanisms could underlie tumor development in recipients: some related to the properties of donor stem cells (including genetic background of the donor) or cells contaminating transplantation material; others to independent stem cell transplantation-related factors affecting a recipient. In this review, these mechanisms are discussed extensively. Discussion is also provided on a number of techniques aimed at preventing donor cell-derived tumor development (a diverse set of approaches which include high-throughput sorting, genetic engineering, etc.).
Transmission of Donor Cell Leukemia (Hematological Malignancies)
Donor stem cells (including bone marrow stem cells (BMSCs), umbilical cord stem cells (UCSCs) and peripheral blood stem cells (PBSCs)) have been used extensively in clinical hematology for decades, for a number of indications. In particular, autologous and/or allogenic hematopoietic stem cell transplantation is indicated in specific clinical cases of leukemia (acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia), lymphoma (Hodgkin's disease and non-Hodgkin lymphoma subtypes) and plasma cell disorders (multiple myeloma). Moreover, the features of BMSC, UCSC and PBSC make these cell types a promising resource for cell replacement or regenerative therapeutic approaches for a wide number of non-hematological disorders, including severe traumas, solid tumors, autoimmune disorders, Parkinson's disease, etc. [1] [2] [3] .
Over the decades of stem cell transplantation (SCT), it has become evident that donor stem cells can cause secondary hematological malignancies in recipients. Two major mechanisms may underlie their development (see analysis in [4, 5] ). First, proliferating donor stem cells can undergo blast transformation under persistent action of certain factors in the recipient (or the factors related to the antileukemic treatment, including radiation therapy), thus causing de novo malignancies (see [6] ). Second, donor stem cells may have already been transformed before the moment of transplantation. Genetic predisposition of donor hematopoietic stem cell to blast transformation (e.g., to hematological malignancies) may be a variation of the latter mechanism. In this sense, reported clinical cases of stem cell transplantation donor and recipient developing genetically identical hematological malignancies synchronously [7] or in a delayed manner [8] are most illustrative. In all cases, the clinical picture is identical for primary and secondary hematological malignancies caused by uncontrolled proliferation of blast cells of host and donor origin; only genetically can these be distinguished. Interestingly, stem cell transplantation is indicated in specific clinical cases, and can induce a remission.
Taken together, a group of secondary hematological malignancies developed via the mechanisms outlined above is termed donor cell leukemia (DCL). Variants of donor cellderived acute myeloid leukemia, including myelodysplastic sydrome, chronic myeloid leukemia, acute lymphoblastic leukemia and lymphomas (in particular, non-Hodgkin's lymphoma) have been reported (see review [9] ), including cases developed considerably after stem cell transplantation. Contemporary literature documents over 50 reported cases of donor cell leukemia development in recipients of BMSC (first case reported in 1971 [10] ; see also [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and see the extensive review on contemporary case reports in [26] ), UCSC [27-32] and PBSC [33-36] transplantation). Available reports suggest donor cell leukemia is a rare complication of allogenic stem cell transplantation [37] : it has been concluded that of all leukemic recurrences following BMSC transplantation, a minor fraction of cases (2%) can be associated with donor cells (see [38] ). Contemporary data suggest that donor cell leukemia occurs with a frequency of 0.13% in allogenic stem cell transplantation [34] . However, one study reports a 5% donor cell leukemia incidence in allogenic stem cell transplantation [39] , and another reports 3% occult hematological malignancy incidence in potential allogenic stem cell transplantation donors screened [40] . While the incidence of recurrent leukemia in host cells diminishes with time [17, 41] , donor cell leukemia tends to occur both early and late, sometimes many years past SCT, with the longest reported gap between stem cell transplantation and donor cell leukemia manifestation being 11 years [42] . Based on their observations, the authors of the latter report also provided the hypothesis that most late relapses occur in donor cells: the longer the interval after stem cell transplantation, the more likely it is that the relapse involves donor cells [42] .
In any case, the risk of developing donor cell leukemia should be taken into account not only for stem cell transplantation for hematological malignancies, but also for BMSC, UCSC and PBSC application to other indications: for either cell replacement or regeneration therapy. Notably, incidences of donor cell leukemia developed following BMSC, UCSC and PBSC transplantation are evidently different, even after correcting for different terms of application in clinical practice (since 1968, 1988 and 1989, respectively) . In view of this observation, peripheral blood stem cells can be considered safer than bone marrow and umbilical cord stem cells for stem cell transplantation.
It should be also mentioned that BMSC and PBSC transplantation carries a risk of development of donor cellderived lymphoproliferative disorders (including immunoblastic lymphoma (immunoblastic sarcoma)). In this case, the mechanism of disease development is based on transmission of particular subtypes of Epstein-Barr Virus (EBV; also human herpesvirus 4, HHV-4) with donor stem cells, under the influence of immunosupression therapy effects. Though rare (first case reported in 1979 [12] ; see also [43] [44] [45] [53, 54] ). These casuistic cases may be due to transmission of donor PBSCs with organs. However, alternative mechanisms can be based on transmission of viral infection (causal for particular leukemia types) with donor cells (see unique case report [55] ). Manifestation of persisting viral infection following immunosupression therapy (essential with organ transplantation) is also possible; see case report on adult T-cell leukemia developing in a human T-cell leukemia virus type I (HTLV-I) carrier receiving a liver transplantation [56] . Indeed, cell therapy per se carries a risk of viral infection transmission, further enhanced by immunosupression therapy enforced in allogenic stem cell transplantationbased approaches. When selecting stem cell donors, this factor should be taken into account. Still, the European Group for Blood and Marrow Transplantation guidelines list viral infections (including EBV, HBV, HCV and CMV) under the 'relative contraindications' and 'specific considerations' sections for stem cell transplantation donor selection [57] .
Transmission of Non-Hematological Malignancies
In addition to the development of donor cell leukemia, a number of clinical cases report incidence of nonhematological malignancies following stem cell transplantation and organ transplantation. For the latter, clinical cases reporting a development of small cell lung carcinoma [58] , pancreatic adenocarcinoma [59] and Kaposi sarcoma [60, 61] in kidney transplant recipients are most illustrative. Numerous reports mention the development of glioblastoma multiforme in the brains of patients who had received liver [62] [63] [64] [65] , kidney [66, 67] and lung [68] transplants. Other histological variants of tumors developed following organ transplantation include malignant meningioma [69] and medulloblastoma [70] . These, and some other reported cases (in particular, see [71] ), have led to important developments in guidelines for donor selection (see [68, 72] ). Most importantly, tumor development in stem cell transplantation recipients can be based on the analogous mechanism: i.e., not on the malignant transformation of donor stem cells (prior to, or following, stem cell transplantation). Instead, a proliferation of malignant cells contaminating the transplantation substrate could be the cause. It is well known that dissemination (metastasis) of tumors occurs with blood flow, in particular. Metastases of certain undiagnosed primary tumors can localize in bones. It therefore should be stressed that in individual clinical cases, PBSC and BMMC material can be contaminated with metastatic donor cells able to cause secondary tumors in stem cell transplantation recipients. It has been previously reported that lung adenocarcinoma, laryngeal squamous cell carcinoma and glioblastoma can develop following allogenic stem cell transplantation [73, 74] .
A number of published case reports list Kaposi sarcoma development in stem cell transplantation recipients [74] [75] [76] [77] . Though this tumor can develop in stem cell transplantation recipients by the mechanism similar to that outlined above, alternative mechanisms of tumor development are possible (see discussion in [74] ). Namely, Kaposi sarcoma may be caused by viral infection transmission with donor stem cells and/or immunosupression therapy associated with allogenic stem cell transplantation [78] .
Intrinsic Stem Cell-Related Mechanisms
Though important, the mechanism of tumor development in stem cell transplantation recipients outlined above can be considered less significant compared to the intrinsic properties of stem cells. Critically, stem cells possess both plasticity (i.e., pluripotency/multipotency) and high proliferation potential, with highest level of both parameters being fundamental to the nature of embryonic stem cells (ESCs). Teratoma (from Greek teras, terat[os]-for monster, deformity) is germ cell tumor that contains cells of two or three germ lines, sometime including derivatives (mature elements). Development of teratoma always occurs as a result of the uncontrollable proliferation of stem cells (namely, ESCs). In experimental research, teratoma development in stem cell transplantation recipients serves as proof of the pluripotency of the studied cells (see comprehensive review [79] ; see also [80] ). Therefore, in case stem cells (namely, ESCs) retaining these properties are present within the stem cell transplantation substrate, teratoma can develop in the transplantation site/sites. Modern literature provides numerous experimental reports on teratoma development in ESC and ESC-derived cell transplantation sites, including brain [81] [82] [83] [84] [85] , liver [86] [87] [88] , joint [89] , heart [90] [91] [92] and in random locations distal from injection sites [93] . This factor was most critical for understanding that the microenvironment in transplantation sites alone does not effectively promote and direct ESC differentiation (see [92] ). It should, however, be noted that, in a few cases, transplantation of undifferentiated ESCs to target organs reportedly has not led to teratoma development [94] [95] [96] . This contradiction could be explained by the expected variability in the host immune response level as a function of transplantation site properties, number of transplanted cells, immunosupression therapy regimen, etc. [82, 92, 97, 98] . Our own experimental study has clearly shown that underdifferentiation of ESC-derivatives is associated with the risk of teratoma development, converging in certain conditions to 100% [85] . This risk is particularly relevant when transplantation is backed with immunosupression therapy (aimed at preventing graft rejection) and/or target 'immunologically privileged organ/ tissue' (e.g., brain). Notably, in our study, teratoma developed in the brains of model animals not subsequent to undifferentiated ESC transplantation, but rather transplantation of a heterogeneous ESC-derived cellular population ( Figs. 1 and 2 ). The latter included ESC-derived functional dopaminergic neurons, i.e. a product of rather prolonged differentiation of ESCs in vitro [85] . Cell sorting (to differentiated and undifferentiated cell fractions) immediately prior to transplantation currently presents a challenge. At the same time, contamination of transplantation substrate with a low number of residual pluripotent cells can be sufficient for teratoma formation following the transplantation. For some sites (i.e., for brain grafting) recipient death is almost inevitable (Fig. 2a, b) .
It should be noted that teratoma development does not constitute the only mode of uncontrollable stem cell proliferation in the transplantation site. Naturally, each proliferating cell acts under a rather strict genetic program directed by its microenvionment. Losing pluripotency, but retaining high proliferation potential, cells may, in a new environment, fail to stop proliferation effectively. Nonteratoma tumors may thus develop in transplantation site/ sites along with 'graft overgrowth' (see below). In particular, we have observed development of tumors histologically similar to schwannoma (neurilemmoma) in brain grafting sites. These tumors (or other non-teratoma tumor types) may be caused by the uncontrolled proliferation of committed ESC-derived cells or other stem cell types with a lower level of plasticity. In particular, a unique case report confirms that tumors can develop in the transplantation site (with a specific host environment) from donor fetal neural stem cells [99] .
Critically, risk of non-teratoma tumor development is mostly associated with ESC-derived cells. Karyotypic changes after many passages in several human ESC lines have been reported [100] [101] [102] [103] . These abnormalities often shorten the doubling times of the cells. Consequently, after several passages, the cells with those abnormalities accumulate in the culture. These changes commonly occur in chromosomes 12 and 17 [104] . Human embryonal carcinoma cell lines commonly have chromosomal abnormalities as well. These abnormalities might cause tumorigenesis after grafting due to their high proliferative capacity, although this remains to be clarified. Furthermore, adult stem cells (namely, MSCs) can also cause tumor development in recipients. Mechanisms of MSC spontaneous malignant transformation must be complex. Karyotypic instability in prolonged culturing in vitro may well be the most important factor; but this hypothesis is in conflict with some reports [105] . Though only a limited number of studies address this important issue [106, 107] , casual reports on MSCs causing tumor development in laboratory experiments should be taken into account [108] [109] [110] .
Finally, so-called 'graft overgrowth' constitutes the most benign variant of excessive donor cell proliferation in transplantation site/sites: e.g., brain ([85, 111, 112] ; see also [113] ) and heart [114] . In this case, donor stem cells (or their progeny) proliferation occurs on a relatively limited scale. However, even a limited proliferation of donor cells in the transplantation site/sites can become a cause of significant side effects expending compression of adjacent anatomical structures and the effect on microcirculation. In brain grafts, proliferation of donor cells in the transplantation site can lead to excessive neurotransmitter production. It is believed that excessive dopamine synthesis by redundant donor cells may contribute to the development of so-called 'graftinduced dyskinesias' (GID) in transplantation recipients (patients with severe Parkinson's disease or parkinsonism) [115] [116] [117] ; it should be noted, though, that this hypothesis conflicts with data reported by Piccini et al. [118] .
Taking into account the risks outlined above, stem cell and progenitor cell types with a moderate level of plasticity and reduced proliferation potential should be generally considered a safer substrate for cell therapy compared to ESCs (Fig. 3) . Considering other essential parameters (ability of particular cell type to survive the transplantation procedure itself, potential to effectively expand cells in vitro, etc.), ESC-derived committed post-mitotic cells can serve as an adequate substrate for cell therapy [119] .
Techniques to Prevent Donor Cell-Derived Tumor Development
Prolonged Differentiation So far, in vitro differentiation of stem cells cannot be synchronized, yielding heterogeneous cell populations containing stem cells, progenitor cells and fully differentiated cells. It is the residual undifferentiated stem cells that can proliferate uncontrollably and differentiate into different cell types which may form tumors/teratomas once grafted into patients. One efficient way to reduce the risk of tumor/teratoma formation is by increasing the cell differentiation status and commitment to the cell type of interest before transplantation, which can be achieved by culturing cells for prolonged periods. This has been mainly shown by us and others when grafting human ESC (hESC)-derived dopaminergic neurons into the brain of animal models of Parkinson's disease. Short-term differentiated hESC cultures, in contrast, may contain residual undifferentiated pluripotent stem cells able to proliferate and differentiate into cells from the three germ-layers in the grafts, causing the formation of teratomas [83, 85, 120, 121] . Additionally, implantation of hESC-derived proliferating neural precursors has resulted in an uncontrolled overgrowth of the grafts, damaging the host brain [111, 121, 122] . We have observed a close relationship between the length of the in vitro differentiation period and teratoma/tumor formation after implantation [85] . As demonstrated in our experiment, while the majority of rats (18/22) 
Although prolonged culturing of stem cells decreases the chances of teratoma/tumor formation, it may reduce graft survival due to an increase of fully mature cells in culture that are more sensitive to the stress associated to the transplantation and the host environment. Again, in the context of transplantation of dopaminergic neurons in Parkinson's disease, the level of maturation of dopaminergic neurons at the time of transplantation markedly affects survival upon implantation [123, 124] . Mature neurons with long processes are more likely to die during mechanical dissociation into a cell suspension for transplantation, due to axotomy [124, 125] . In our own experience, grafts of hESCs that had been left to differentiate longer in vitro tended to exhibit lower numbers of mature neurons [85] . Additionally, further extension of the in vitro differentiation protocol makes it more costly and can further elevate cell composition variability.
This problem has been recently overcome by Ko et al. [126] by introducing the transgenes for Bcl-XL (antiapototic protein from Bcl-2 family with a role on neuronal survival) and sonic hedgehog (SHH, a signaling molecule secreted during development that promotes neuronal proliferation and survival in the adult brain) into hESC-derived neural precursor cells. Besides increasing graft survival, transduction of hESC-derived neural precursors with Bcl-XL and SHH enhanced cell survival during extensive expansion in vitro. The prolonged in vitro expansion eliminated highly proliferative neuroepithelial cells and reduced the number of residual undifferentiated OCT-3/4-positive (POU5F1-positive) cells. Therefore, when implanted into the brain of Parkinsonian rats, these cells did not cause teratoma formation. The presence of residual undifferentiated stem cells was also shown to be dependent on the presence of basic fibroblast growth factor (bFGF, FGF-2) in the culture medium (and most probably not present in transplantation sites), increasing the chances of tumor/teratoma formation. Therefore, when implanted into the brain of Parkinsonian rats, these cells did not cause teratoma formation [126] . In conclusion, an optimal culturing period that eliminates tumor/teratoma-forming stem cells in combination with a method to increase cell survival after transplantation is a good strategy to enhance the safety and success of a stem cell-based therapy. 
High-Throughput Cell Sorting
Fluorescence-activated cell sorting (FACS) [127, 128] and biomagnetic (MACS) techniques utilizing any recognized marker cell surface antigens (or rather combinations of the latter) expressed either by undifferentiated (negative selection) or committed and differentiated (positive selection) cells presents another interesting possibility (see comprehensive study [129] ). In particular, the latter study suggests using SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 as markers of immature hESCs; SSEA-1, FORSE-1, CD29, CD146, A2B5 and p75 as markers of neural stem and precursor cells; and NCAM (CD56) as a marker of differentiated hESC progeny. Numerous other markers for cells at various stages of stem cell to differentiated cell transition are available [130] .
Modern technology allows effective application of robotic high-throughput sorting tools, ensuring rapid and reliable sorting of large volume of cells. It should be noted however, that cell processing in the step preceding sorting and the cell sorting procedure itself affects cell viability. Considering the fact that the heterogeneous cell population subject to the sorting may include cells highly sensitive to any mechanical and chemical stress (namely, differentiated neurons), both FACS and MACS techniques can contribute to decreasing cell viability, thus decreasing any functional effect which could be achieved by transplanting hESC-derived dopaminergic neurons. Though, these sorting techniques may be useful for transplantation of more robust cells. Interestingly, genetic manipulation-based approaches, i.e., cell transduction with fluorescence-labeled specific constructs or application of fluorogenic substrates for target cell-specific enzymes to improve FACS specificity [129] are technologically feasible. It is suggested that additional high-throughput cell sorting methods (based on microfluidics and optical switches) could become available for this application in the future [131, 132] .
Introduction of Suicide Genes
One of the strategies of controlling graft overgrowth or tumor development is genetic engineering of donor cells with suicide genes prior to transplantation. If the grafted cells become tumorigenic, the suicide genes can be activated in the graft, inducing programmed cell death. For example, herpes simplex virus thymidine kinase (HSV-TK, also HSVtk) can be transduced into donor cells (including hESCs) prior to transplantation. Importantly, genetically modified cells retain the characteristic properties of ES cells [133] . In this system, when the tumors were produced by the HSV-TK-positive hESCs, tumor growth was stopped and the tumor mass was eliminated upon Ganciclovir treatment [133] . Ganciclovir (GCV) is a prodrug which becomes toxic when it is phosphorylated by HSV-TK, changing to its triphosphate form and incorporating into DNA, leading to cell death.
Grafting of HSV-TK-positive mouse ESCs (mESCs) into brains of NOD/SCID mice results in tumor formation. Subsequent treatment of the animals with Ganciclovir completely eliminated the tumors derived from the transduced ESCs [134] . This data suggests that is possible to control cell outgrowth via genetic modification of donor ESCs. Notably, incorporation of fluorescent proteins to the construct allows a reliable molecular imaging of suicide geneinduced ESC ablation [133] [134] [135] . Other suicide genes potentially suitable for ESC genetic modifications include a tetracycline-inducible form of the diphtheria toxin and bacterial cytosine deaminase. Taken together, the combination of genetic engineering with cell therapy (so-called gene/cell therapy-based approaches) presents a promising strategy for selective ablation of residual undifferentiated hESCs present in the heterogeneous cell populations being grafted. However, apparent risks associated with gene therapy (genetic modification of proliferating pluripotent cells in particular) require caution in any laboratory-to-clinic transition step.
Epigenetic Factors Affecting Undifferentiated Cells
A simple and attractive approach to eliminate residual undifferentiated stem cells from cell cultures is to add pharmacological agents that target exclusively those cells. Bieberich et al. [136] [137] [138] showed that addition of ceramide or ceramide-analogues to mouse or human ESC cultures eliminated the undifferentiated cells, but spared those that had differentiated into neural progenitors expressing nestin. Ceramide or ceramide analogue-induced apoptosis of undifferentiated ESCs is mediated by the prostate apoptosis response-4 (PAR-4), an endogenous inhibitor protein of atypical PKC. However, the majority of ESC-derived precursors (e.g. nestin-positive) do not express PAR-4 and are thus resistant to ceramide-induced apoptosis. In another study, the ceramide analogue, N-oleoyl serinol (S18) has been applied in vitro to induce apoptosis of residual proliferative mESCs within embryoid bodies (EB). Following dissociation of the embryoid bodies and MACS sorting to remove apoptotic cells, the remaining cells were transplanted into the mouse striatum. Although they yielded significantly fewer teratomas than control grafts of cells from untreated embryoid bodies, tumors were not completely prevented. The tumors that formed were almost exclusively nestin-positive, indicating that they were of neural progenitor origin, rather than derived from proliferating ESCs [138] .
More recently, Choo et al. [139] developed, for the first time, a cytotoxic antibody that binds specifically to undifferentiated hESCs and induces cell death. By immunization of mice with live hESCs, a panel of monoclonal antibodies (mAbs) was generated. One of those antibodies, mAb 84, which reacted with podocalyxin-like protein-1 (PODXL), specifically bound to undifferentiated hESCs, eliminating the latter population. Therefore, treatment of hESCs with mAb 84 prior to transplantation into severe combined immunodeficient (SCID) mice resulted in no teratoma formation, in contrast with transplants of nontreated cells. Furthermore, the binding reactivity of mAb 84 was decreased when hESCs were induced to differentiate into embryoid bodies, showing the specificity of this antibody to undifferentiated hESCs. Moreover, this antibody was shown to react with different hESC lines, including HES-2, -3 and -4. Although the mechanism by which mAb 84 kills hESCs when binding PODXL it is not known, the authors have suggested that it might be through oncosis [139] . In conclusion, even though mAb 84 appears to be an efficient agent for eliminating potential tumorigenic undifferentiated hESCs, its safety remains to be evaluated for clinical applications.
Epigenetic Factors Affecting Tumor Cells
Chemotherapy is a widely used strategy for cancer therapy. Identifying drugs, chemicals or other compounds that either selectively kill residual pluripotent stem cells or malignantly transformed cells, or which arrest their proliferation, would have much potential in stem cell-based applications. Such drugs or chemicals would be used in vitro before transplantation, as strategies to eliminate unwanted cells, which may cause side effects once transplanted into patients, and leaving the therapeutic cell types unaffected. For example, mitomycin C, an agent that permanently arrests cell division, could be used before transplantation [140, 141] . Development of new agents with similar properties but fewer risks might be useful.
HAMLET (human alpha-lactalbumin made lethal to tumor cells) is another interesting candidate. Human alpha-lactalbumin (a comonent of breast milk) can be converted from its native state to a folding variant entitled HAMLET [142] . It has been demonstrated that HAMLET selectively induces cell death in tumor cells (presumably, via a few independent pathways, see [143] ) while sparing differentiated cells [144, 145] . In experiment, HAMLET was able to selectively kill tumor cells and control tumor progression without apparent tissue toxicity [146] . Most interestingly, when administered to bladder cancer patients, HAMLET stimulated a rapid increase in the shedding of dead tumor cells into the urine, induced morphological changes in the tumors and caused reduction in tumor size and alterations in tumor structure [147] . It should be noted that, so far, a relatively limited volume of data has been generated in the experiments employing HAMLET or its bovine analogue BAMLET (bovine alpha-lactalbumin made lethal to tumor cells). However, available data suggests that HAMLET can be viewed as a candidate factor able to prevent tumor formation in stem cell grafts. It still remains to be shown whether this drug is specific for unwanted residual undifferentiated stem cells, while sparing the stem cell-derived therapeutic cell types that we aim to purify.
Irradiation
It has long been recognized that various cells have different sensitivities to radiation. In particular, BMSCs are highly sensitive to radiation, with bone marrow being a target of radiation lesions both in accidents and in antileukemic treatment. Numerous reports confirm adult cells, progenitor cells and stem cell subtypes vary in their sensitivity to radiation (see [148] [149] [150] ). It is theoretically possible to define an irradiation dose reliably antimitotic for highly proliferative stem cells while not affecting differentiated cells in stem cell differentiation protocols. This task is complicated by the fact that committed progenitors (presenting the most advantageous substrate of cell therapy) and some types of differentiating and differentiated cells (namely, functional neurons) are highly sensitive to irradiation [151] [152] [153] . Moreover, there are conflicting reports on the sensitivity of stem cells to radiation compared to progenitor cells and certain adult cell subtypes. The highly flexible biological status of differentiating stem cells and genetic variations in cultured cells (see [154] ) thus makes finding an appropriate dose of radiation (most probably, a very low dose) able to ablate undifferentiated stem cells but not other cell types problematic. In our own studies, very low dose γ-irradiation (30 cGy to 2 Gy) was able to partially inhibit hESC spontaneous differentiation in vitro, yet it was not able to suppress spontaneous differentiation completely (concordant to data reported in [154] ), while higher doses induced massive cell death in dividing hESCs (Fig. 4) .
The growth and maintenance of different types of tumors, such as brain glioblastomas and colon cancer, are considered to be caused by the presence of cancer stem cells, probably originated from the transformation of stem cells [155] . Treatments of those tumors should then particularly target these cells. However, available reports indicate cancer stem cells might be relatively insensitive to chemotherapy (hypothetically, through the mechanism associated with high expression of anti-apoptotic IL-4 ligand and receptor; [156] ) and irradiation (hypothetically, due to increased activation of the DNA damage checkpoint; see [157, 158] ) treatment. We believe that distinct metabolic features of those cells further illustrate a complexity of practical application of irradiationbased cell selection strategies.
Other Options
Enhancing differentiation in vitro by a variety of means appears the most straightforward approach to reduce the tumorigenicity of heterogeneous cell populations yielded by hESC differentiation. Less orthodox approaches could be based on the application of various factors acting posttransplantation. This allows targeting of donor cell proliferation in the grafting site without further decreasing donor cell viability at pre-transplantation step and throughout the cell transplantation procedure itself. It has been reported that injection of folate antagonist methotrexate (MTX; candidate neuronal differentiation induction factor) to the brain grafting site, 1 week post transplantation of mESC, partially suppresses teratoma formation [159] . This example suggests that principles different from those outlined in the subsections above could underlie approaches aiming to reduce and effectively eliminate existing risks of tumor formation in patients transplanted with stem cells and stem cell-derived cells.
Conclusions
Taken together, numerous types of malignancies can arise from donor stem cells of different types, not limited to mesenchymal stem cells (MSCs) or embryonic stem cells (ESCs). As discussed above, a spectrum of highly diverse mechanisms could underlie tumor development in recipients. In some cases a contamination of transplantation material with metastatic cells of donor origin or undiagnosed blast transformation of donor HSCs can cause a development of hematological and non-hematological malignancies in stem cell transplantation recipients in a straightforward manner. In other cases, intrinsic biological properties characteristic to stem cells (e.g., teratoma formation caused by residual ESCs present in heterogeneous transplanted cell populations) or even less evident mechanisms (e.g., viral infection attenuated by stem cell transplantation-associated immunosupression) could be responsible. It would be an oversimplification to conclude that unlike ESCs, MSCs are completely safe in terms of tumor development in the recipient. Though recorded exclusively in experiment, reduction of spontaneous malignant transformation of MSCs cultured in vitro for a prolonged time (required for large-scale applications) is reported by a limited number of studies. It is therefore essential to consider this factor in MSC applications.
While procedural means (screening donors for hidden viral infections, etc.) can partially compensate for some oncological risks, it is still critical to develop approaches that selectively eliminate tumorigenic cells in heterogeneous cell population before or after transplantation into patients. In the current review, we have discussed a few approaches which are radically different in principle, ranging from high-throughput cell sorting to cell treatment with factors selectively inducing cell death in undifferentiated stem cells. It should be stressed that currently none of the options outlined above allows removing the risks of tumor formation in stem cell transplantation recipients completely. However, rapid progress in this subject makes us believe that such a method (potentially based on the combination of different approaches) will be developed in the near future.
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